April 01, 2026 05:17 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India | ‘Unsubstantial allegations’: Calcutta HC dismisses plea on ECI’s officer transfers in Bengal | Tennis icon Leander Paes joins BJP ahead of Bengal polls | 8 killed, several injured in crowd crush at Bihar temple in Nalanda | Trump signals exit from Iran war even as Strait of Hormuz remains shut: Report | Mystery death in Pakistan: JeM chief Masood Azhar’s brother found dead
South Korea COVID-19
Image: Wallpaper Cave

South Korea approves first oral Covid pill treatment

| @indiablooms | Dec 27, 2021, at 10:26 pm

Seoul/UNI/Sputnik: South Korea’s Ministry of Food and Drug Safety on Monday approved Pfizer’s oral antiviral pill, the first one to treat Covid-19 in the country, after a panel of experts reviewed its safety and efficiency, national media said.

Pfizer’s Paxlovid is a pill treatment of mild-to-moderate Covid-19 cases for people 12 years of age and older weighing at least 88 pounds with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe Covid-19, including hospitalization or death, according to the US Food and Drug Association.

Paxlovid is not a substitute for vaccination for those whom Covid-19 vaccination and a booster shot are advised. It is administered by prescription only.

Paxlovid consists of three tablets taken together orally twice a day for five days.

The treatment should be administered as soon as possible after diagnosis of Covid-19 and within five days of symptom onset, according to Pfizer.

Paxlovid is believed to reduce the risk of hospitalisation or death among patients at high risk of severe illness by 88 percent.

Currently, South Korea uses Remdesivir and Rekirona intravenous injections to treat critical cases and to reduce the risk of infection progressing to severe cases, respectively.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.